Technova raised 2026 revenue guidance on broad-based growth, but cell-and-gene weakness and elevated spending delay profitability.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-08-05 |
| Length | 45 minutes |
| EPS | $-0.06 |
| EPS consensus | $-0.08 |
| Revenue | $11.1M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
All TKNO earnings ยท Back to TKNO overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.